Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Status:
Active, not recruiting
Trial end date:
2024-05-03
Target enrollment:
Participant gender:
Summary
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the
efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
Phase:
Phase 2
Details
Lead Sponsor:
EMD Serono EMD Serono Research & Development Institute, Inc.